This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
The Zacks Analyst Blog Highlights Eli Lilly, AbbVie, Gilead Sciences, Air T and Fossil Group
by Zacks Equity Research
Eli Lilly, AbbVie, Gilead Sciences, Air T and Fossil Group are included in this Analyst Blog.
Top Stock Reports for Eli Lilly, AbbVie & Gilead Sciences
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), AbbVie Inc. (ABBV) and Gilead Sciences, Inc. (GILD), as well as two micro-cap stocks, Air T, Inc. (AIRT) and Fossil Group, Inc. (FOSL).
FDA Accepts GSK's Filing for Expanded Use of Nucala in COPD
by Zacks Equity Research
The FDA accepts GSK's regulatory filing seeking the expanded use of Nucala in COPD treatment for review.
AZN's Bladder Cancer sBLA for Imfinzi Gets FDA's Priority Tag
by Zacks Equity Research
FDA grants priority review to AZN's sBLA seeking expanded use of Imfinzi for muscle-invasive bladder cancer.
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for IBB
TARA Stock Soars on Superior Efficacy of Bladder Cancer Cell Therapy
by Zacks Equity Research
Protara stock surges 70% as investigational cell therapy, TARA-002, shows superior six-month efficacy in phase II bladder cancer study.
FDA Accepts Roche's Columvi sBLA for Expanded Use in Lymphoma
by Zacks Equity Research
The FDA accepts RHHBY's sBLA seeking the label expansion of Columvi to include the treatment of second-line R/R DLBCL for review.
PCRX Receives New Patent for Lead Pain Drug Exparel in the US
by Zacks Equity Research
The U.S. Patent and Trademark Office grants a new patent to protect the chemical composition of Pacira's lead pain-management drug, Exparel.
ITCI Submits sNDA to the FDA for Expanded Use of Caplyta in MDD
by Zacks Equity Research
Intra-Cellular submits an sNDA to the FDA, seeking the label expansion of Caplyta to treat MDD in adults as an adjunctive therapy to antidepressants.
Gilead Collaborates With German Biotech Tubulis for Solid Tumor ADC
by Zacks Equity Research
GILD and Germany-based Tubulis collaborate to discover and develop an antibody-drug conjugate against a solid tumor target.
PPBT Stock Surges 150% on Superior Efficacy of PDAC Combo Therapy
by Zacks Equity Research
Purple Biotech stock surges 150.4% on reporting superior efficacy data from the mid-stage study of its combo therapy on pancreatic cancer patients.
NVCR Stock Up as TTFields Therapy Meets Pancreatic Cancer Study Goals
by Zacks Equity Research
Novocure stock soars 49% as the late-stage study of TTFields therapy for treating pancreatic adenocarcinoma meets the primary endpoint of overall survival.
Is Gilead (GILD) a Buy as Wall Street Analysts Look Optimistic?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Gilead (GILD) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Should You Invest in the iShares Biotechnology ETF (IBB)?
by Zacks Equity Research
Sector ETF report for IBB
Here's Why You Should Add Dr. Reddy's Stock to Your Portfolio
by Zacks Equity Research
RDY enjoys a strong foothold in the global generics market due to its deep generic drugs pipeline. Its efforts to strengthen its biosimilars portfolio are commendable.
Gilead Stock Surges 44.2% in 6 Months: Time to Buy or Sell?
by Zacks Equity Research
GILD has put up a solid performance in the past six months on positive data readouts and strong quarterly results. We believe there is more room for growth, given GILD's strong fundamentals.
GILD vs. VRTX: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
GILD vs. VRTX: Which Stock Is the Better Value Option?
RDY Launches Loqtorzi Biosimilar in India for Nasopharyngeal Carcinoma
by Zacks Equity Research
Dr. Reddy's launches Loqtorzi biosimilar in India under the brand name Zytorvi for treating adults with recurrent or metastatic nasopharyngeal carcinoma.
OTLK Stock Falls on Failure to Meet Non-Inferiority Goal in AMD Study
by Zacks Equity Research
Outlook Therapeutics stock tanks 65% as ONS-5010 fails to meet the pre-specified non-inferiority endpoint at week 8 in the 90-day NORSE EIGHT study for wet AMD.
APLT Stock Plunges 77% After FDA Issues CRL for Galactosemia Drug NDA
by Zacks Equity Research
Applied Therapeutics stock plummets 77% after the FDA issues a CRL for the company's NDA seeking approval for govorestat to treat classic galactosemia.
Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know
by Zacks Equity Research
Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
ACAD Signs License Deal With Saniona for Rights to Neurology Drug
by Zacks Equity Research
Acadia signs a $610 million exclusive global license agreement with Saniona to develop and commercialize SAN711 for neurological disorder indications.
Roche to Acquire CAR-T Cell Therapy Focused Poseida for $1.5B
by Zacks Equity Research
RHHBY is all set to acquire Poseida Therapeutics, Inc. and ramp up its pipeline with off-the-shelf cell therapies.
AbbVie Stock Rises After Leerink Partners Upgrades Its Rating
by Zacks Equity Research
Leerink Partners upgrades its rating on ABBV stock from Market Perform to Outperform.
Novartis Raises Sales Outlook for Mid-Term, Acquires Kate Therapeutics
by Zacks Equity Research
NVS expects sales to witness a CAGR of 6% during 2023-2028, up from the earlier projection of 5%. The company acquires Kate Therapeutics to strengthen its portflio of gene therapies.